AI Science Tracker
EN

Development and internal validation of an interpretable machine learning-based risk stratification model for sarcopenic obesity in patients with type 2 diabetes mellitus.

Affiliation not stated in the reviewed material · 2 Nov 2026 · medicine

Discovery

Development and internal validation of an interpretable machine learning-based risk stratification model for sarcopenic obesity in patients with type 2 diabetes mellitus.

Source check: Source checked. Not independent scientific confirmation.

Finding: Interpretable ML models including LightGBM and XGBoost stratify sarcopenic obesity risk in a 378-patient single-centre T2DM cohort with internal validation and calibration.

Technology: Interpretable LightGBM and XGBoost models for sarcopenic-obesity risk stratification.

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
LightGBM and XGBoost models use clinical variables to estimate sarcopenic-obesity risk in patients with type 2 diabetes.
Test and result
A 378-patient single-centre T2DM cohort was split for model development and internal validation; calibration and discrimination were assessed for sarcopenic-obesity risk.
Limitation / still unknown
External generalization, independent replication and downstream real-world impact were not established by the reviewed source.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1893262/full

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.